Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure
- PMID: 20371568
- PMCID: PMC2887273
- DOI: 10.1677/JOE-09-0397
Genetic and pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in rodent models of heart failure
Abstract
The central melanocortin system plays a key role in the regulation of food intake and energy homeostasis. We investigated whether genetic or pharmacologic blockade of central melanocortin signaling attenuates cardiac cachexia in mice and rats with heart failure. Permanent ligation of the left coronary artery (myocardial infarction (MI)) or sham operation was performed in wild-type (WT) or melanocortin-4 receptor (MC4R) knockout mice. Eight weeks after surgery, WT-Sham mice had significant increases in lean body mass (LBM; P<0.05) and fat mass (P<0.05), whereas WT-MI did not gain significant amounts of LBM or fat mass. Resting basal metabolic rate (BMR) was significantly lower in WT-Sham mice compared to WT-MI mice (P<0.001). In contrast, both MC4-Sham and MC4-MI mice gained significant amounts of LBM (P<0.05) and fat mass (P<0.05) over the study period. There was no significant difference in the BMR between MC4-Sham and MC4-MI mice. In the second experiment, rats received aortic bands or sham operations, and after recovery received i.c.v. injections of either artificial cerebrospinal fluid (aCSF) or the melanocortin antagonist agouti-related protein (AGRP) for 2 weeks. Banded rats receiving AGRP gained significant amount of LBM (P<0.05) and fat mass (P<0.05) over the treatment period, whereas banded rats receiving aCSF did not gain significant amounts of LBM or fat mass. These results demonstrated that genetic and pharmacologic blockade of melanocortin signaling attenuated the metabolic manifestations of cardiac cachexia in murine and rat models of heart failure.
Figures




Similar articles
-
Melanocortin antagonism ameliorates muscle wasting and inflammation in chronic kidney disease.Am J Physiol Renal Physiol. 2012 Nov 1;303(9):F1315-24. doi: 10.1152/ajprenal.00341.2012. Epub 2012 Aug 22. Am J Physiol Renal Physiol. 2012. PMID: 22914778 Free PMC article.
-
Differential role of melanocortin receptor subtypes in cachexia.Endocrinology. 2003 Apr;144(4):1513-23. doi: 10.1210/en.2002-221099. Endocrinology. 2003. PMID: 12639936
-
Modulation of melanocortin signaling ameliorates uremic cachexia.Kidney Int. 2008 Jul;74(2):180-6. doi: 10.1038/ki.2008.150. Epub 2008 Apr 23. Kidney Int. 2008. PMID: 18432186
-
Update on melanocortin interventions for cachexia: progress toward clinical application.Nutrition. 2010 Feb;26(2):146-51. doi: 10.1016/j.nut.2009.07.003. Epub 2009 Dec 8. Nutrition. 2010. PMID: 20004082 Free PMC article. Review.
-
Melanocortin interventions in cachexia: how soon from bench to bedside?Curr Opin Clin Nutr Metab Care. 2007 Jul;10(4):457-62. doi: 10.1097/MCO.0b013e328108f441. Curr Opin Clin Nutr Metab Care. 2007. PMID: 17563464 Review.
Cited by
-
Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia.J Clin Invest. 2020 Sep 1;130(9):4921-4934. doi: 10.1172/JCI138392. J Clin Invest. 2020. PMID: 32544087 Free PMC article.
-
Research on cachexia, sarcopenia and skeletal muscle in cardiology.J Cachexia Sarcopenia Muscle. 2012 Dec;3(4):219-23. doi: 10.1007/s13539-012-0090-6. Epub 2012 Nov 16. J Cachexia Sarcopenia Muscle. 2012. PMID: 23160775 Free PMC article.
-
Muscle wasting and cachexia in heart failure: mechanisms and therapies.Nat Rev Cardiol. 2017 Jun;14(6):323-341. doi: 10.1038/nrcardio.2017.51. Epub 2017 Apr 24. Nat Rev Cardiol. 2017. PMID: 28436486 Review.
-
Diverging metabolic programmes and behaviours during states of starvation, protein malnutrition, and cachexia.J Cachexia Sarcopenia Muscle. 2020 Dec;11(6):1429-1446. doi: 10.1002/jcsm.12630. Epub 2020 Sep 28. J Cachexia Sarcopenia Muscle. 2020. PMID: 32985801 Free PMC article. Review.
-
Hypothalamic activation is essential for endotoxemia-induced acute muscle wasting.Sci Rep. 2016 Dec 6;6:38544. doi: 10.1038/srep38544. Sci Rep. 2016. PMID: 27922103 Free PMC article.
References
-
- Anker SD, Sharma R. The syndrome of cardiac cachexia. International Journal of Cardiology. 2002;85:51–66. - PubMed
-
- Anker SD, Ponikowski P, Varney S, Chua TP, Clark AL, Webb-Peploe KM, Harrington D, Kox WJ, Poole-Wilson PA, Coats AJ. Wasting as independent risk factor for mortality in chronic heart failure. Lancet. 1997;349:1050–1053. - PubMed
-
- Anker SD, Ponikowski PP, Clark AL, Leyva F, Rauchhaus M, Kemp M, Teixeira MM, Hellewell PG, Hooper J, Poole-Wilson PA, et al. Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure. European Heart Journal. 1999;20:683–693. - PubMed
-
- Anker S, Steinborn W, Strassburg S. Cardiac cachexia. Annals of Medicine. 2004;36:518–529. - PubMed
-
- Baskin DG, Hahn TM, Schwartz MW. Leptin sensitive neurons in the hypothalamus. Hormone and Metabolic Research. 1999;31:345–350. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical